KONTROL' VZAIMODEYSTVIYa«LIGAND-RETsEPTOR» NA N1-RETsEPTORAKh

Abstract


Обсуждены данные о передаче сигнала с гистаминовых (Н1) рецепторов в свете новых сведений о заня-
тости рецептора как форме предсказания лечебной эффективности Н1-антигистаминных препаратов.

I S Gushchin

  1. Dale H.H., Laidlaw P.P. The physiological action of β-imidazolylethylamine. J. Physiol. (Lond.) 1910, v. 41, p. 318-344.
  2. Гущин И.С. Аллергическое воспаление и его фармакологи- ческий конт роль. М., «Фармарус Принт». 1998, 252 с.
  3. Гущин И.С. Антагонисты Н1-рецепторов как противоаллер- гические лекарственные средства (обзор). Тер. архив. 1997, № 10, с. 27-34.
  4. Liu Y.J. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation.J. Allergy Clin. Immunol. 2007, v. 120, p. 238-244.
  5. Wang Y.H., Liu Y.J. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J.Clin.Invest. 2007, v. 117, p. 3655-3657.
  6. Seshasayee D., Lee W.P., Zhou M. et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 2007, v. 117, p. 3868-3878.
  7. Гущин И.С. Спонтанная («конститутивная») активность и обратный агонизм на Н1-рецепторах. Рос. аллергол. журн. 2006, № 2, с. 3-14.
  8. Simons F.E.R., ed. Histamine and H1-receptor antagonists in allergic disease. New York. «Marcel Dekker, Inc». 1996. 424 p.
  9. Gether U. Uncovering molecular mechanisms involved in activation of G-protein-coupled receptors. Endocr. Rev. 2000, v. 21, p. 90-113.
  10. Le Coniat M., Traifford E., Ruat M. Et al. Chromosomal localization of the human histamine H1-receptor gene. Hum. Genet. 1994, v. 94, p. 186-188.
  11. Kuhn B., Schmid A., Harteneck C. et al. G proteins of the Gq family couple the H2 histamine receptor to phospholipase C. Mol. Endocrinol. 1996, v. 10, p. 1697-1707.
  12. Bakker R.A., Schoonus S.B.J., Smit M.J. et al. Histamine H1-receptor activation of nuclear factor-κB: roles for Gβγ- and Gαq/11-subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 2001, v. 60, p. 1133-1142.
  13. Strasser A., Striegl B., Wittmann H.J., Seifert R. Pharmacological profile of histaprodifens at four recombinant histamine H1-receptor species isoforms. J. Pharmacol. Exp. Ther. 2008, v. 324, p. 60-71.
  14. Nguen T., Shapiro D.A., George S.R. et al. Discovery of novel member of the histamine receptor family. Mol. Pharmacol. 2001, v. 59, p. 427-433.
  15. Nakamura T., Itadani H., Hidaka Y. et al. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem. Biophys. Res. Commun. 2000, v. 279, p. 615-620.
  16. Liu C., Ma X., Jiang X. et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol. Pharmacol. 2001, v. 59, p. 420-426.
  17. Oda N., Morikawa N., Saita Y. et al. Molecular cloning and characterization of novel type of histamine receptor preferentially expressed on leukocytes. J. Biol. Chem. 2000, v. 275, p. 36781-36786.
  18. Hashimoto T., Harusawa S., Araki L. et al. A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5-[1 H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methyl-guanidine. J. Med. Chem. 2003, v. 46, p. 162-165.
  19. Liu C., Wilson S.J., Kuei C. et al. Comparison of human, mouse, rat, and guinea pig histamine H4-receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 2001, v. 299, p. 121-130.
  20. Hofstra C.L., Desai P.J., Thurmond R.L., Fung-Leung W.P. Histamine H4-receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 2003, v. 305, p. 1212-1221.
  21. Gantner F., Sakai K., Tusche M.W. et al. Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J. Pharmacol. Exp. Ther. 2002, v. 303, p.300-307
  22. Takeshita K., Sakai K., Bacon K.B., Gantner F. Critical role of histamine H4-receptor in leukotriene B4 production and mast-cell-dependent neutrophil recruitment induced by zymosan in vivo. J. Pharmacol. Exp. Ther. 2003, v. 307, p. 1072-1078.
  23. Huang J.F., Thurmond R.L. The new biology of histamine receptors. Curr. Allergy Asthma Rep. 2008, v. 8, p. 21-27.
  24. Dunford P.J., Williams K.N., Desai P.J. et al. Histamine H4 -receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J.Allergy Clin. Immunol. 2007, v. 119, p. 176-183.
  25. Dillon P.F., Root-Bernstein R.S., Lieder C.M. Ascorbate enhancement of H1 histamine receptor sensitivity coincides with ascorbate oxidation inhibition by histamine receptors. Am. J. Physiol. 2006, v. 291, p. C977-C984.
  26. Iriyoshi N., Nakeuchi K., Yuta A. et al. Increase expression of H1R mRNA in allergic rhinitis. Clin. Exp. Allergy. 1996, v. 26, p. 379-385.
  27. Dinh Q.T., Cryer A., Dinh S. et al. Transcriptional up-regulation of histamine receptor-1 in epithelial, mucus and inflammatory cells in perennial allergic rhinitis. Clin. Exp. Allergy. 2005, v. 35, p. 1443-1448.
  28. Terada N., Hamano N., Maesako K.I. et al. Diesel exhaust particulates up-regulate histamine receptor mRNA and increase histamine-induced IL-8 and GM-CSF production in nasal epithelial cells and endothelial cells. Clin. Exp. Allergy. 1999, v. 29, p. 52-59.
  29. Fukui H. Progress in allergy research on mast cells: up-regulation of histamine signal-related gene expression in allergy model rats.J.Pharmacol.Sci. 2008, v. 106, p. 325-331.
  30. Miyoshi K., Das A.K., Fujimoto K. et al. Recent advances in molecular pharmacology of the histamine systems: regulation of histamine H1-receptor signaling by changing its expression level.J.Pharmacol.Sci. 2006, v. 101, p. 3-6.
  31. Miyoshi K., Kawakami N., Das A.K. et al. Heterologus up-regulation of the histamine H1-receptor by M3 muscarinic receptor-mediated activation of H1-receptor gene transcription. J.Pharm.Pharmacol. 2007, v. 59, p. 843-848.
  32. Гущин И.С. Холинергическая система и особенности фарма- кологического вмешательства в нее некоторых антагонистов Н1-рецепторов. Рос. Аллергол. журн. 2005, № 6, с. 3-15.
  33. Гребенченко Е.И., Гущин И.С., Феденко Е.С. Кожная чувстви- тельность к ацетилхолину у больных атопическим дерматитом и поллинозом. Рос. аллергол. журн. 2008, № 1, с. 19-23.
  34. Царев С.В. Хлоропирамин (супрастин) в лечении аллергических заболеваний. Рос. аллергол. журн. 2006, № 6, с. 63-64.
  35. Латышева Т.В. Хлоропирамин в ургентной аллергологии. Рос. аллергол. журн. 2006, № 3, с. 68-72.
  36. Ильина Н.И., Лусс Л.В., Тузлукова Е.Б. Опыт применения комбинированной терапии супрастином и парлазином больных хронической рецидивирующей крапивницей. Рос.аллергол. журн. 2007, № 1, с. 71-74.
  37. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999, v. 18, p. 6867-6874.
  38. Hu O., Deshpande S., Irani K. et al. [Ca2+]i oscillation frequency regulates agonist-stimulated NF-κB transcripti-onal activity. J. Biol. Chem. 1999, v. 274, p. 33995-33998.
  39. Hart L.A., Krishnan V.L., Adcock I.M. et al. Activation and localization of transcription factor, nuclear factor-?B, in asthma. Am. J. Respir. Crit. Care Med. 1998, v. 158, p. 1585-1592.
  40. Desmet C., Gosset P., Pajak B. et al. Selective blockade of NF-kappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J. Immunol. 2004, v. 173, p. 5766-5775.
  41. Poynter M.E., Cloots R., Van Woerkom T. NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness. J.Immunol. 2004, v. 173, p. 7003-7009.
  42. Catley M.C., Chivers J.E., Holden N.S. et al. Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br. J. Pharmacol. 2005, v. 145, p. 114-122.
  43. Bakkouri E.L., Wullaert A., Haegman M. et al. Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J. Biol. Chem. 2005, v. 280, p. 17938-17944.
  44. Na H.J., Moon P.D., Ko S.G. et al. Sargassum hemiphyllum inhibits atopic allergic reaction via the regulation of inflammatory mediators. J. Pharmacol. Sci. 2005, v. 97, p. 219-226.
  45. Peng Y., Power M.R., Li B., Lin T.J. Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB pathway in IgE-dependent mast cell activation. J. Leukoc. Biol. 2005, v. 77, p. 975-983.
  46. Caramori G., Adcock I.M., Ito K. Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD. Curr. Opin. Investig. Drugs. 2004, v. 5, р. 1141-1147.
  47. Buddenkotte J., Stroh C., Engels I.H. et al. Agonists of proteinase-activated receptor-2 stimulate upregulation of intercellular cell adhesion molecule-1 in primary human keratinocytes via activation of NF-kappa B. J. Invest. Dermatol. 2005, v. 124, p. 38-45.
  48. Asano K., Kanai K.I., Suzaki H. Suppressive activity of fexofenadine hydrochloride on metalloproteinase production from nasal fibroblasts in vitro. Clin. Exp. Allergy. 2004, v. 34, p. 1890-1898.
  49. Edwards M.R., Mukaida N., Johnson M., Johnston S.L. IL-1beta induces IL-8 in bronchial cells via NF-kappaB and NF-IL6 transcription factors and can be suppressed by glucocorticoids. Pulm. Pharmacol. Ther. 2005, v. 18, p. 337-345.
  50. Chowdhury B.A., Kaliner M.A. Molecular identification of the H1-receptor in humans. In: F.E.R.Simons, ed. Histamine and H1-receptor antagonists in allergic disease. New York. «Marcel Dekker, Inc.» 1996, p. 33-60.
  51. Bakker R.A., Dees G., Carrillo J.J. et al. Domain swapping in the human histamine H1 receptor. J. Pharmacol. Exp. Ther. 2004, v. 311, p. 131-138.
  52. Bruysters M., Jongejan A., Gillard M. et al. Pharmacological differences between human and guinea pig histamine H1 receptors: Asn84(2.61) as key residue within an additional binding pocket in the H1 receptor. Mol. Pharmacol. 2005, v. 67, p. 1045-1052.
  53. Kiss R., Kovari Z., Keseru G.M. Homology modeling and binding site mapping of the human histamine H1 receptor. Eur. J. Med. Chem. 2004, v. 39, p. 959-967.
  54. Milligan G., Bond R.A., Lee M. Inverse agonism: phar-macological curiosity or potential therapeutic strategy? Trends Pharmacol. Sci. 1995, v. 16, p. 10-13.
  55. Church M. Histamine receptors, inverse agonism, and allergy. J. World Allergy Organization. 2004, v. 16, p. 112-116.
  56. Leurs R., Church M.K., Taglialatela M. H1-antihistamines : inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Exp. Allergy. 2002, v. 32, p. 489-498.
  57. Bakker R.A., Wieland K., Timmerman H., Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur. J. Pharmacol. 2000, v. 387, p. R5-R7.
  58. Govoni M., Bakker R.A., van de Wetering I. et al. Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists. J. Med. Chem. 2003. v. 46, p. 5812-5824.
  59. Гущин И.С. Кардиотоксическое действие антагонистов Н1-гистаминовых рецепторов. Клин. фармакол. и терапия. 1998, № 3, с. 82-86.
  60. Frossard N., Strolin-Benedetti M., Purohit A. et al. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br. J. Clin. Pharmacol. 2008, v. 65, p. 172-179.
  61. Tillement J.-P. A low distribution volume as a determinant of efficacy for histamine (H1) antagonists. Allergy. 1995, v. 50, p. 12-16.
  62. Gillard M., Strolin Benedetti M., Chatelain P., Baltes E. Histamine H1-receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm. res. 2005, v. 54, p. 367-369.
  63. del Cuvillo A., Millol J., Bartra J. et al. Comparative pharmacology of H1-antihistamines. J. Investig. Allergol. Clin. Immunol. 2006, v. 16, suppl.1, p. 3-12.
  64. Grant J.A., Danielson L., Rihoux J.P., De Vas C. A double blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy. 1999, v. 54, p. 700-707.
  65. Warner J.O., ETAC Study Group. A double blind, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J.Allergy Clin. Immunol. 2001, v. 108, p. 929-937.
  66. Мадьяр К. Рандомизированное перекрестное исследование биоэквивалентности однократной дозы препаратов Парла- зин и Зиртек таблетки, на здоровых мужчинах-добровольцах. Будапешт, Венгрия, 2000. Научное досье компании Эгис (цит. по [69]).
  67. Фассахов Р.С., Решетникова И.Д., Сукманская Е.О. и соавт. Эффективность и безопасность терапии цетиризином (пар- лазином) больных аллергическим ринитом. Рос. аллергол. журн. 2006, № 1, с. 65-66.
  68. Филатова Т.А., Ревякина В.А., Кондюрина Е.Г., Зеленская
  69. В.В. Парлазин в лечении атопического дерматита у детей. Вопр. совр. педиатрии. 2005, № 2, с. 109-112.Макарова И.В., Жиглинская О.В., Михайлова Е.А., Су- хорукова В.Г. Сравнительная эффективность препаратов цетиризина дженерика (производство Эгис, Венгрия) и оригинального в форме капель в комплексной терапии ато- пического дерматита у детей раннего возраста. Вопр. совр. педиатрии. 2007, № 3, с. 85-88.

Views

Abstract - 8

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2008 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies